| AFL |
Report |
Adjusted EPS |
BEAT |
pred ~$1.88 vs. cons $1.84 |
MEDIUM |
| AFL |
Report |
Aflac Japan total benefit ratio |
BEAT |
pred ~61.5% vs. cons 62.2% |
MEDIUM |
| AFL |
Report |
Aflac Japan new annualized premium sales |
BEAT |
pred ~¥21.6B vs. cons ¥21.0B |
MEDIUM |
| AFL |
Guide |
Aflac Japan full-year sales aspiration |
BETTER |
guide ~¥80B vs. cons ¥79.5B (FY2026) |
MEDIUM |
| AFL |
Guide |
Aflac Japan benefit ratio |
UNCHANGED |
guide ~61.5% vs. cons 61.5% (FY2026) |
HIGH |
| AFL |
Guide |
Aflac U.S. benefit ratio |
UNCHANGED |
guide ~50.0% vs. cons 50.0% (FY2026) |
HIGH |
| AFL |
Guide |
Aflac Japan underlying earned-premium growth |
UNCHANGED |
guide ~-1.5% vs. cons -1.5% (FY2026) |
MEDIUM |
| AFL |
Guide |
Aflac Japan cyber-incident cost and operating-impact commentary |
BETTER |
guide ~$10M vs. cons $20M (2H2026) |
LOW |
| AFL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| AFL |
Return |
5-day cumulative residual |
+0.5% (STABILIZE) |
A modest EPS and Japan-sales beat (~$1.88 vs. $1.84 and ~¥21.6B vs. ¥21.0B) is likely offset by largely unchanged FY2026 benefit-ratio and underlying-premium guidance (~61.5% vs. 61.5% and ~-1.5% vs. -1.5%), limiting out-period estimate revisions after an initially positive reaction. |
MEDIUM |